NCT03755791Phase 3Active not recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy

Study sponsor: Exelixis

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2021-11-30Actual

Enrollment · participants837Actual

Source updated2025-12-11Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-12-11 · 1 field changed

Primary completion date

Recorded edit

− Previous value

2021-03-08

+ Updated value

2021-11-30

Check registry source

Posted 2025-11-24 · 1 field changed

Primary outcomes · main study measures

Text edit · unverified significance

− Previous value

measure: Duration of Progression Free Survival (PFS) for the experimental arm vs. the control arm; measure: Duration of Overall Survival (OS) for the experimental arm vs. the control arm

+ Updated value

measure: Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population; measure: Overall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population

The saved outcome text may be shortened. Check the source for full wording.

Check registry source

Study details

Conditions studied

Hepatocellular Carcinoma

Treatments or interventions studied

CabozantinibDrugAlso known as XL184, Cabometyx®
CabozantinibDrugAlso known as XL184, Cabometyx®
SorafenibDrugAlso known as Nexavar®
AtezolizumabDrugAlso known as Tecentriq®

Primary outcomes · main study measures

Read the study measures

measure: Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population; description: PFS was defined as the time from randomization to the earlier of either the date of radiographic progression defined as a 20% increase in the sum of the longest diameters of target lesions, or the unequivocal appearance of new lesions, or progression of non-target disease per Blinded Independent Radiology Committee (BIRC) or the date of death due to any cause per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.; timeFrame: From the date of first participant randomization up to 28 months; measure: Overall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population; description: OS was defined as the time from randomization to death due to any cause.; timeFrame: From the date of first participant randomization up to 36 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history